Reversibility of trastuzumab induced cardiotoxicity in breast cancer patients: A prospective observational study

Krikez, I.; Benmalek, R.; Bennouna, G.; Drighil, A.; Azzouzi, L.; Habbal, Rachida

doi:10.1016/j.acvdsp.2019.09.086

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, since Trastuzumab was given in combination with chemotherapy the direct effect of trastuzumab on cardiac function in isolation is difficult to estimate. Furthermore, a prospective observational study of patients receiving trastuzumab treatment revealed 6/38 TIC cases were irreversible despite optimal cardioprotective therapy [ 10 ]; while another study showed lower mean LVEF in BC patients with history of trastuzumab-related cardiotoxicity, than in patients without such history, even up to 7-years post-treatment [ 11 ]. Again, the latter study was performed in patients of whom 90% had received anthracycline chemotherapy prior to Trastuzumab, which precludes attribution of cardiac effects to trastuzumab alone.…”

Section: Trastuzumab-mediated Cardiotoxicity In Patientsmentioning

confidence: 99%

“…anthracyclines) when used in combination [ 3 , 6 , 9 ]. Alongside potentially irreversible cardiovascular decline [ 8 , 10 , 11 ], treatment-induced cardiotoxicity (TIC) may require interruption of therapy, which itself can have potentially serious repercussions with respect to overall patient survival [ 12 ]. As such, development of treatment strategies to limit the cardiotoxicity of trastuzumab adjuvant therapy is critically important to improve its success.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?

Eaton

Timm

2023

Cardio-Oncology

View full text Add to dashboard Cite

The use of the adjuvant therapeutic antibody trastuzumab in breast cancer is associated with a range of cardiotoxic side effects despite successfully reducing the severity of outcomes cancer patients,. The most common cardiac effect, a reduction in left ventricular ejection fraction (LVEF), is a known precursor to heart failure and often requires interruption of chemotherapy to avoid endangering patients further. An understanding of trastuzumab’s cardiac-specific interactions is therefore critical in devising new methods to not only avoid permanent cardiac damage, but also prolong treatment time, and therefore effectiveness, for breast cancer patients. Increasingly, the use of exercise as a treatment has been indicated across the field of cardio-oncology due to encouraging evidence that it can protect against LVEF reductions and heart failure. This review explores the mechanisms of trastuzumab-mediated cardiotoxicity, as well as the physiological effects of exercise on the heart, in order to assess the suitability of exercise intervention for breast cancer patients on trastuzumab antibody-therapy. We furthermore draw comparison to existing evidence for exercise intervention as a cardioprotective treatment in doxorubicin-induced cardiotoxicity. Although preclinical evidence seems to support exercise-based approaches also in trastuzumab-cardiotoxicity, current clinical evidence is too limited to confidently recommend it as a treatment, largely owing to issues of adherence. Future studies should therefore examine how the variety and duration of exercise can be adjusted to improve treatment effectiveness at a more personalised level.

show abstract

Section: Trastuzumab-mediated Cardiotoxicity In Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?

Eaton

Timm

2023

Cardio-Oncology

View full text Add to dashboard Cite

show abstract

“…Other new drugs are currently being discussed and with promising achievements, this is the case of Poxvirus JX-594, which is an oncolytic virus used in hepatocellular carcinoma [28,29], NY-ESO-1 [30], Trastuzumab [31,32], Anti VEGF [33] and Bevacizumab [34,35].…”

Section: Virotherapymentioning

confidence: 99%

Update on Gene Therapy as an Antineoplastic Alternative

Sánchez¹,

León²,

Hurtado³

et al. 2021

OAJBS

View full text Add to dashboard Cite

The 21 st century has revolutionized medicine and with it the emergence of new treatment trends and the improvement of others not so new where gene therapy is found; an alternative that is gaining space in the profiles of cancer therapy. With the aim of describing the main characteristics of gene modification techniques and their use in cancer treatment or as an adjuvant in traditional treatments, 35 bibliographic references were reviewed where it was pointed out that: even though cancer is a monogenic disease, it is one of the main targets for this practice. The main techniques are aimed at strengthening our body and promoting neoplastic self-destruction in different ways. Gene therapy is an antineoplastic alternative that, although it is not a cure, promises to obtain very good results in the future.

show abstract

Reversibility of trastuzumab induced cardiotoxicity in breast cancer patients: A prospective observational study

Cited by 2 publications

References 0 publications

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?

Update on Gene Therapy as an Antineoplastic Alternative

Contact Info

Product

Resources

About